Infectious Disease Testing

Platelia Aspergillus Ag Assay
EIA for screening, diagnosing and monitoring invasive aspergillosis (IA)in high-risk patients

Visit bio-rad.com/diagnostics for more information.

Unique, High-Performance
Platelia Aspergillus Ag Assay
Immunosuppressed patients are at-risk
populations for invasive fungal infections
such as invasive aspergillosis (IA). Due todifficulties in diagnosing IA in a reliable
and timely manner, the IA mortality rates
are very high (for example, ranging from70-93% in hematopoietic stem cell transplant
recipients). Early diagnosis is critical for
effective treatment and to avoid costlyantifungal therapy.

Aids in High-Risk Patient Diagnosis
The Platelia Aspergillus Ag assay is a unique tool
for screening, monitoring, and diagnosing invasive

The Platelia Aspergillus Ag Assayfor galactomannan detection isboth reliable and rapid.

aspergillosis in high-risk patients including:■

Neutropenic hematological patients■

Non-neutropenic patients with hematological diseases■

Solid-organ transplant recipients and ICU patients

Platelia Aspergillus Ag Assay Benefits

3 hrs

■

Standardized EIA format is easy to perform and interpret■

Results are reported as index values

Platelia Aspergillus Ag Assay

Microplate format (with breakable strips) is easily
adaptable to each application

Results obtained within 3 hours■

VSGold standard assay forgalactomannan detection
in diagnosing invasiveaspergillosis (IA)severaldays
Traditional Mycological Tests
Results obtained within several days

© 2021 Bio-Rad Laboratories, Inc.

Targeting Galactomannan
For diagnosing invasive aspergillosis (IA)Through detection of the galactomannan
antigen, the non-invasive Platelia
Aspergillus Ag assay allows physicians toGalactomannan

screen, diagnose, and monitor invasive
aspergillosis in conjunction with otherdiagnostic procedures.
Located in the Aspergillus cell wall,galactomannan is considered a reliable
marker for invasive aspergillosis diseasebecause circulating galactomannan
antigen (GM) is released during active

Antibody to
Galactomannaninvasive aspergillosis.

ScreenDiagnose

MonitorGalactomannan Antigen
First Qualified Clinical Biomarker for IA
Defined by the EORTC/MSG
Consensus Group
Galactomannan antigen detection using
the Platelia Aspergillus Ag assay is among
the mycological criteria defined by theEORTC/MSG Consensus Group.

© 2021 Bio-Rad Laboratories, Inc.

Galactomannan Draft Guidance
In 2014, the FDA Center for Drug Evaluation
and Research (CDER) approved galactomannanantigen (GM) testing by Platelia Aspergillus Ag as
the first clinical biomarker qualified through theBiomarker Qualification Program.

Platelia Aspergillus Ag Assay for invasive aspergillosis detection
Validated on serum and bronchoalveolar lavage (BAL) fluid specimens for adult patients and serum for pediatric patients.
Convenient■ 96-well microplate with breakable strips■Ready-to-use, colored reagents (diluents, calibrators,conjugate, chromogen)

Secured
Visual control of sample dilution and reagent deposit
Objective
Provides semi-quantitative results (galactomannan index values)

RapidFeatures rapid turnaround time (3 hours compared withseveral days using conventional methods)
Reliable■ Excellent sensitivity and specificity from oncohematology
adult samples■

Faster initiation of appropriate treatment and monitoringof effectiveness

Recommended Testing Systems

Complementary Assays

The Bio-Rad fully automated EVOLIS systems or
stand-alone systems (IPS/PR4100/PW40) arerecommended instruments for testing with the Platelia
Aspergillus Ag assay.

The Platelia Aspergillus Ag assay is a noninvasive
method that improves the rapid and specific diagnosis
of invasive aspergillosis (IA) when used in conjunction
with other diagnostic procedures. The Bio-Rad EIA offerwith Platelia Candida Ag Plus, Platelia Candida Ab Plus,and Platelia Aspergillus Ag assays is a reliable solution
for detection at the right time during main invasive
fungal infections.

EVOLIS System
EVOLIS Twin Plus System

Contact your Bio-Rad representative to learn more about our Platelia Aspergillus Ag Assay, testing instruments, and world classtechnical support.
Visit bio-rad.com/diagnostics for more information.

Ordering Information
Catalog No.

Description

62794

Platelia Aspergillus Ag. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .96 tests

62792

Platelia Aspergillus Proficiency Panel.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 x 6 tests

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.
PLATELIA and EVOLIS are trademarks of Bio-Rad Europe, GmbH in certain jurisdictions.

Bio-RadLaboratories, Inc.
ClinicalDiagnostics Group

Bulletin 16043 Rev FWebsite www.bio-rad.com/diagnostics Australia +61 (2) 9914 2800 Austria +43 (0) 1 877 89 01 9 Belgium +32 (0) 3 710 53 00 Brazil +55 11 3065 7550
Canada +1 514 334 4372 China +86 21 6169 8500 Czech Republic +420 241 431 660 Denmark +45 44 52 10 00 Finland +358 9 804 22 00
France +33 (0)1 47 95 60 00 Germany +49 (0) 89 31884 393 Greece +30 210 7774396 Hong Kong +85 2 2789 3300 Hungary +36 1 459 6190
India +91 124 4029300 Israel +972 03 963 6025 Italy +39 024 94 86 600 Japan +81 3 6361 7070 Korea +82 080 007 7373 Mexico +52 (55) 5488 7670
The Netherlands +31 (0)318 540 666 New Zealand +64 (9)415 2280 Norway +47 23 38 41 30 Poland +48 22 331 99 99 Portugal +351 21 47 27 700
Russia +7 495 721 1404 Singapore +65 6415 3170 South Africa +27 11 442 8508 Spain +34 91 490 6580 Sweden +46 844 98053
Switzerland +41 (0) 61 717 9555 Taiwan +886 (2) 2578-7189 Thailand (662) 651 8311 United Kingdom +44(0)1923 471301© 2020 - 6858

© 2021 Bio-Rad Laboratories, Inc. 2021/08